SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a dramatic surge to new 52-week highs, driven by high call option activity and a substantial short interest, sparking widespread anticipation of an intensifying gamma and short squeeze. The community is actively discussing the company's momentum as a commercial-stage leader in cancer treatment, with many seeing potential for significant long-term wealth creation.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending amidst anticipation for its Q4 earnings, driven by its strategic pivot into AI/HPC data centers, recent significant capacity expansions, and new analyst coverage with a $37 price target. The community is actively discussing a potential short squeeze given high short interest, viewing the company as an emerging AI infrastructure play increasingly decoupled from Bitcoin volatility.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is experiencing high volatility following mixed earnings that reported strong subscriber growth but weak forward guidance and significant regulatory and litigation risks concerning its weight-loss segment. The community is fiercely divided, with many anticipating a massive short squeeze due to high short interest, while others remain cautious, highlighting the ongoing legal uncertainties.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

Vir Biotechnology is actively discussed following its substantial collaboration with Astellas Pharma for a prostate cancer immunotherapy, fueled by positive early clinical data and robust financial results, sparking community debate about its valuation and potential for a short squeeze amidst a tight share float.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is a major talking point ahead of its anticipated earnings report, with strong community sentiment around a potential 18th consecutive beat and raise, despite broader software sector sell-offs. Investors are actively discussing the company's proprietary AI and extensive data moat, bolstered by its OpenAI partnership, as key differentiators that could drive future growth and a significant short squeeze.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

Rich Sparkle Holdings (ANPA) is trending with extreme volatility following its acquisition of TikTok icon Khaby Lame's core company and a recent private placement. The community is sharply divided, with many speculating on further parabolic moves for this Hong Kong low-float stock, while others express strong skepticism, labeling it an overvalued 'pump and dump' amidst concerns about its fundamental valuation and potential share dilution.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is actively discussed following its partnership with Anthropic to embed AI into financial apps, a move the community views as either a significant moat expansion or an attempt to counter broader AI disruption fears weighing on the SaaS sector. This development intensifies speculation regarding its upcoming earnings and the stock's current deeply oversold valuation.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is facing a sharp sell-off amid sector-wide fears that AI, particularly Anthropic's Claude Code Security, will disrupt traditional cybersecurity, a narrative amplified by the company's lowered profit outlook despite a revenue beat. The community is actively debating whether these AI advancements will make cybersecurity obsolete or, conversely, drive increased demand for robust defense platforms.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending following a notable stock decline driven by market concerns that Anthropic's AI tool for COBOL modernization could disrupt its legacy mainframe business. However, a strong counter-narrative from analysts and the community suggests this is an overreaction, pointing to IBM's strategic partnership with Anthropic and its own robust AI solutions for enterprise modernization, positioning the dip as a potential buying opportunity.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and decor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending after its Q4 earnings saw an EPS beat offset by a sales miss and cautious forward guidance, sparking community debate about the impact of housing market weakness versus resilient professional customer demand, alongside a noted dividend increase.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IMMP so first in Q1 expected the futility analyses on Tacti-004 
 
Then also in first half of 2026, 
update on IMP761 
 
The LAG-3 (lymphocyte-activation gene-3) immune checkpoint has been identified as a promising therapeutic target for many autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.1-3 IMP761 is the first LAG-3 agonist antibody developed to potentially treat these large, increasingly prevalent disorders, each of which represent multi-billion dollar markets. 
 
These 3 mentioned immune diseases are markets combined worth around 90 billion dollars in 5 of 6 years.  
https://www.immutep.com/immutep-announces-positive-update-on-imp761-a-first-in-class-lag-3-agonist-antibody-for-autoimmune-diseases-from-phase-i-study/ 
 
The Eftisarc neo trial, anybody knows when we can expect news on that?

Marco

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable safety profile Substantial reduction in T cell activity highlights the potential efficacy of IMP761 in treating autoimmune diseases Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, AUSTRALIA, Dec.

Immutep | LAG-3 Immunotherapy for Cancer & Autoimmune Disease

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

StockTwits Web

Immutep LTD ADR

 so first in Q1 expected the futility analyses on Tacti-004 
 
Then also in first half of 2026, 
update on IMP761 
 
The LAG-3 (lymphocyte-activation gene-3) immune checkpoint has been identified as a promising therapeutic target for many autoimmune diseases, including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.1-3 IMP761 is the first LAG-3 agonist antibody developed to potentially treat these large, increasingly prevalent disorders, each of which represent multi-billion dollar markets. 
 
These 3 mentioned immune diseases are markets combined worth around 90 billion dollars in 5 of 6 years.  


 
 
The Eftisarc neo trial, anybody knows when we can expect news on that?